Korean in-vitro diagnostics company, Osang Healthcare, led the financing as a strategic investor. Existing investors also participated.
San Diego-based Allez — founded by experts in the continuous glucose monitoring (CGM) space — plans to use the new capital to accelerate growth toward pivotal trials, support regulatory approval filings and scale manufacturing operations.
Key figures in the leadership team include Chief Technology Officer Robert Boock and Chief Science Officer Ted Zhang. Boock served as lead inventor of the Dexcom G4 CGM and Zhang led development for G4’s sensor membrane. Advisor Frank Westerman co-founded mySugr, which Roche acquired in 2017. Leif Bowman, who held senior leadership positions in marketing at Dexcom from 2008 to 2016, co-founded the company and serves as CEO.
Allez Health develops a CGM biosensor platform with novel sensor technology. The company hopes to disrupt the current cost barrier to CGM while enhancing performance and user experience. According to Allez’s website, it offers a 15-day wear time with real-time data and eco-friendly components.
To date, Allez has seven issued patents and more than 40 pending patent applications. It’s taken part in more than 80 clinical studies aggregating more than 1,500 users, plus a pivotal study in 120 users, according to a news release.
Having completed its pivotal study and secured investment, the company hopes to accelerate toward commercialization.
“We believe that person-centric health is critical for optimal health solutions,” Bowman said. “We aim to bring to market a sensor that combines access, affordability, and reliable performance, because when it comes to an individual’s health, no one should have to choose between price and performance.”
